Slide 1: Stock exchange cover letter for Investor Presentation Q4 FY25
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/TG/2025-26/24 May 09, 2025 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corpor
Slide 2: Biocon Limited Q4 & Full Year FY25 Earnings Call
Biocon Limited Q4 & Full Year FY25 Earnings Call 09 - MAY - 2 0 2 5 The Multiplier Effect MAXIMIZING VALUE
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements made during the call concerning the future growth prospects of the Company may be forward-looking statements, which are subject to number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in s
Slide 4: Chairperson Opening Remarks
Chairperson Opening Remarks
Slide 5: Opening Remarks: Q4 & Full Year FY25 Performance Overview
Opening Remarks: Q4 & Full Year FY25 Performance Overview Peter Bains appointed as Chief Executive Officer and Managing Director of Syngene International Global launch of our first GLP-1 formulation, Liraglutide, in the UK, and launch of Lenalidomide and Dasatinib in the U.S. Launched Yesintek (bUst
Slide 6: Financial Highlights Q4 and Full Year FY25
Financial Highlights Q4 and Full Year FY25
Slide 7: Financial Highlights – Q4 FY25
Financial Highlights – Q4 FY25 In ₹ Cr Q4 FY25 Q4 FY24 Q3 FY25 YoY% QoQ% (Adj.) Generics 1,048 718 686 46 53 Biosimilars 2,463 2,358 2,289 9@ 8 Research Services 1,018 917 944 11 8 Revenue from Operations 4,417 3,917 3,821 151 16 Total Revenue 4,454 3,966 3,856 151 16 Core EBITDA3 1,363 1,176 1,007
Slide 8: Financial Highlights – FY25
Financial Highlights – FY25 In ₹ Cr FY25 FY24 YoY% (Adj.) Generics 3,017 2,799 8 Biosimilars 9,017 8,824 15@ Research Services 3,642 3,489 4 Revenue from Operations 15,262 14,756 101 Total Revenue 16,470 15,621 8.2 Core EBITDA3 4,264 4,196 32 % Margin 28 29 R&D (Net) 859 1,154 (26) % of Revenue (Ex.
Slide 9: Generics Q4 and Full Year FY25
Generics Q4 and Full Year FY25
Slide 10: Biocon Generics: Q4 & FY25 Business Performance Update
Biocon Generics: Q4 & FY25 Business Performance Update Q4 Q4 Q3 In ₹ Cr YoY% QoQ% FY25 FY24 FY25 Strongest quarterly performance driven by the launch of Lenalidomide in the US. Performance further boosted by the launch of Liraglutide in the Operating Revenue 1,048 718 686 46 53 UK and Dasatinib in t
Slide 11: Biosimilars Q4 and Full Year FY25
Biosimilars Q4 and Full Year FY25
Slide 12: Biocon Biologics: Q4 & FY25 Business Performance Update
Biocon Biologics: Q4 & FY25 Business Performance Update Q4 Q4 Q3 YoY% Key product and site approvals from regulators incl. USFDA & EMA In ₹ Cr QoQ% FY25 FY24 FY25 (Adj.)1 USFDA approval for Jobevne (bBevacizumab) and positive EU Operating Revenue 2,463 2,358 2,289 9 8 CHMP opinion for bDenosumab Cor
Slide 13: Research Services Q4 and Full Year FY25
Research Services Q4 and Full Year FY25
Slide 14: Syngene: Q4 & FY25 Business Performance Update
Syngene: Q4 & FY25 Business Performance Update Quarterly operating revenue crossed the ₹1,000 crores threshold for In ₹ Cr Q4 Q4 Q3 YoY% QoQ% the first time FY25 FY24 FY25 Operating Revenue 1,018 917 944 11 8 Acquisition of a state-of-the-art biologics facility in the U.S. enhances capabilities in t
Slide 15: Concluding Remarks
Ing. Conclud . y GENOMIC INSPIRATION
Slide 16: Concluding Remarks: Q4 & Full Year FY25
Concluding Remarks: Q4 & Full Year FY25 FY25 has been a year of consolidation and of transition Biocon on a path of accelerating growth with a commitment to innovation, digital augmentation and operational excellence
Slide 17: Q&A
Q&A The Multiplier Effect MAXIMIZING VALUE